#4655
A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumours
Introduction:
Somatostatin receptor 2 (SST2) is an established target for the treatment of NETs and potentially other solid tumours.
Conference:
Presenting Author:
Authors:
Zhao J,
Sturchler E,
Yang B,
Chen M,
Tang Y,
Keywords:
somatostatin,
solid tumour,
drug conjugate,
internalisation,
cytotoxicity,
#3925
Telomerase-independence function of Dyskerin is therapeutic vulnerability in TP53 mutant pancreatic neuroendocrine tumors
Introduction:
Pancreatic neuroendocrine tumors (PanNETs) utilize the recombination-mediated alternative lengthening of telomeres (ALT) mechanism, rather than telomerase, for the maintenance of telomeres.
Conference:
Presenting Author:
Ji S
Authors:
Ji S,
Lou X,
Zhou C,
Xu X,
Chen J,
Keywords:
pancreatic neuroendocrine tumor,
tp53 mutant,
dyskerin,
temozolomide,
#3536
Comparison of drug sensitivity profiles of various NEN spheroids
Introduction:
Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Small bowel and pancreatic NETs (SBNET & PNETs) are generally slow-growing but commonly metastasize to the liver and become aggressive cancers. Little is known about the drug sensitivity profile of these 3 NENs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NEN cells from patient tumors as patient-derived spheroids (PDS) and showed expression of NEN markers. The rarity and slow growing features of these spheroids have been hindering drug screens with many compounds.
Conference:
Presenting Author:
Ear P
Authors:
Tran C,
Luis B,
Sherman S,
Mudd J,
Abusada E,
Keywords:
NET,
NEC,
spheroid,
drug screening,
PDX model,
#2898
Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction:
The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Ear P
Authors:
Ear P,
Tran C,
Li G,
Kaemmer C,
Ellen A,
Keywords:
SBNET,
drug screening,
spheroids,
PDX models,
precision medicine,
